Strides Fast-Tracks China Entry With JV As It Reports Strong Q1
Indian firm Strides announces its entry into China through a joint venture with one of the country’s leading pharmaceutical firms, as first-quarter EBITDA soars 155%.
You may also be interested in...
India’s Strides has received a warning letter from the US Food and Drug Administration over compliance issues at its Puducherry plant. However, the firm has told investors the regulatory action will not affect its forecast of 20% US sales growth for this financial year.
China's National Health Commission issues list of 34 generic drugs that have 'insufficient' competition, seeking public comments.
Strides Pharma “very confident” about future after Indian generic company’s fourth-quarter US revenues rocketed 181% and EBITDA margins beat market expectations.